1423 POSTER Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)
| Autor: | Miles, D.W., De Haas, S.L., Romieu, G., Chan, A., Dirix, L., Cortes, J., Delmar, P.R., Scherer, S.J. |
|---|---|
| Zdroj: | In European Journal of Cancer 2011 47 Supplement 1:S176-S176 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect